Better Long-Term Buy: Eli Lilly or Viking Therapeutics?
Key Points Eli Lilly has been a growth beast, coming off an impressive year in which its revenue rose by 45%. Viking Therapeutics has an exciting GLP-1 drug in development that, if approved, could send its shares skyrocketing. 10 stocks we like better than Eli …